I role in promoting specific mechanisms of host defense.
Of particular importance are its immunomodulatory effects, which include induction of Fc receptors and major histocompatibility complex (MHC) class I and class 11 antigens, regulation of cytokine gene expression (eg, interleukin-1 [IL-I], IL-6, and tumor necrosis factor [TNF]), and promotion of activation and differentiation of numerous immune effector cells including monocytes and B cells. Specifically, IFNy has been shown to modulate B-lymphocyte function by influencing Ig synthesis and Ig class selection. In contrast to its broad mechanism of action, IFNy production in vivo is tightly regulated, as synthesis of ZFNy messenger RNA (mRNA) has been detected only in activated T cells and large granular lymphocytes (LGLs). 14 
IFNy production by T cells and LGLs can be stimulated
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact. This is a US govemment work. There are no restrictions on its use. 0006-4971 /92/8003-0014$0.00/0 (PKC) activators, phorbol 12-myristate 13-acetate (PMA) and (-)Indolactam-v, to secrete IFNy, whereas JLP(c) cells spontaneously produce low levels of IFNy that can be enhanced by PKC activators and interleukin-2 (IL-2). After activation of the cell lines with IL-2, (-)Indolactam-v, and PMA, increases in cytoplasmic messenger RNAs (mRNAs) of IFNy and the IL-2 receptor chains were also observed. The induction of IFNy mRNA and protein by IL-2 was completely blocked by a monoclonal antibody to IL-2 receptor p75 (fi chain), but not by the monoclonal antibody to p55 (achain). Analysis of IFNy genomic DNA indicates that the gene is not amplified, but that hypomethylation in the 5' noncoding region of the IFNy gene has occurred in the B-cell line from the Burkitt's lymphoma patient that spontaneously produces IFNy. This finding suggests that the methylation state of the promoter region may play an important role in the control of IF& gene expression in B cells. This is a US government work. There are no restrictions on its use.
by various comp0unds.I IFNy production in vivo appears to be regulated by cellular interactions between helper, suppressor, and IFNy-producing T cells and LGLs, with IL-2 produced by the T cells acting as an important mediator of IFNy expression, especially in the LGLs.
LGLs need only one signal to produce IFNy (eg, IL-2, phytohemagglutinin [PHA], phorbol-12-myristate-13-acetate [PMA] , or calcium ionophore), whereas T cells require two signals. Physiologically, one T-cell signal is provided by a specific antigen and the other signal comes from an antigen-presenting cell bearing class I1 MHC protein. In vitro, the two signals can be mimicked with a combination of mitogens (eg, PHA) and phorbol esters or cytokines (eg, IL-2). 5, 6 In both LGLs and T cells, protein kinase C (PKC) activity seems to be involved in the signal transduction leading to IFNy gene transcripti~n.~j~ Furthermore, both PMA and IL-2 have been shown to increase IFNy expression after transfection of the human IFNy genomic DNA into a murine T-cell line.8~9
Based on biologic and immunologic assays, there have been scattered reports of IFNy production in cell types other than T cells or LGLs. These cell types include alveolar macrophage,IO a human myelomonocytic cell line," and a Hodgkin's lymphoma cell line.Iz It has previously been reported that JLP(c), an Epstein-Barr virus (EBV)-positive pre-B-cell line derived from a patient with Burkitt's lymphoma, secretes IFNy. 13 In this report, we have further characterized the expression of IFNy by JLP(c) cells and compare it with IFNy produced by PA682BM-1, an EBV-positive intermediate-hell line derived from a patient with acquired immunodeficiency syndrome (AIDS) and Burkitt's lymphoma. Analysis of the molecular and biochemical pathways involved in the synthesis and secretion of IFNy by these B-cell lines indicates that the secretion of B-cell IFNy is stimulus-dependent and is mediated via PKC. Whereas the production of IFNy was
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enhanced by IL-2, PMA, or (-)Indolactam-v in JLP(c) cells, the synthesis of IFNy was triggered by PMA and (-)Indolactam-v, but not by IL-2, in PA682BM-1. These differences correlate with the level of expression of the IL-2 receptor (IL-2R) P chain mRNA in the two cell lines [ie, high in JLP(c) and low in PA682BM-11, indicating that the mechanism of I G 2 induction of IFNy expression in B-cell lines is similar to that seen in L G h . Furthermore, we provide evidence that hypomethylated DNA in the promoter region of the IFNy gene is present in the B-cell line that spontaneously expresses IFNy mRNA and protein.
MATERIALS AND METHODS
Cell lines. JLP(c) is an EBV-positive cell line with an 8;14 chromosomal translocation derived from a patient with Burkitt's lymphoma; PA682BM-1 is an EBV-positive, human immunodeficiency virus-1 (HIV-1)-negative cell line with an 8;22 chromosomal translocation derived from a patient with AIDS and Burkitt's lymphoma. JD39 is an EBV-negative cell line with an e14 chromosomal translocation obtained from a patient with undifferentiated lymphoma of Burkitt's type. JD39 cells do not express IFNy, and this cell line served as a negative control. The derivation of these B-cell lines has been previously described.14 The Jurkat cell line and U937 cell line were originally obtained from the American Type Culture Collection (Rockville, MD). The mouse T-lymphoblastoid line containing human IFNy genomic DNA has been previously described? The Jurkat cell line capable of producing IFNy was obtained from Dr Chris Wilson (University of Washington, Seattle, WA). All cell lines were grown in RPMI 1640 medium (Whittaker Bioproducts, Walkersville, MD) and supplemented with 10% fetal bovine serum, 2 mmol/L L-glutamine, 100 U/mL of penicillin, and 100 pg/mL of streptomycin. All cell lines were tested by the Mycoplasma Testing Laboratory (Program Resources, Frederick, MD) and were confirmed to be mycoplasmafree.
The antibodies used in these studies Cytofluorometric analysis was performed as previously described.15 Briefly, 1 x 106 cells were incubated at 4°C for 30 minutes in Hanks' balanced salt solution containing 1% bovine serum albumin (BSA) and 0.05% sodium azide (NaN3), with saturating amounts of antibody. After incubation, samples were washed two times in the same buffer. Binding was analyzed on a FACScan (Becton Dickinson) using the FACScan research software program. To examine cytoplasmic Igs, we used the same method after treating the cells with L-lysophosphalidylcholine (Sigma Chemical, St Louis, MO).
Genomic DNA was purified from cell lines with proteinase K digestion, phenol-chloroform extraction, ethanol precipitation, and RNase A digestion, as previously described.16 Cellular DNA (10 pg) was digested with 50 U of the designated restriction enzyme at 37°C overnight. For analysis of Ig heavy chain and TCRB receptor gene rearrangement~,'~,~~HindlII, BamHI, EcoRI, or Sst I were each used separately. For analysis of
Monoclonal antibodies (MoAbs).
FACScan analysis.
Southem blot analysis.
IFNy gene rearrangement and methylation, BamHI was performed first, followed by SnaBI digestion. This latter restriction enzyme was recently reported to be sensitive to methylation of cytosine in its recognition sequence. 19 After electrophoresis in an 0.8% agarose gel, DNA was transferred to a nylon membrane (Nytran; Schleicher and Schuell, Keene, NH), UV crosslinked, and hybridized at 42"C, as previously reported. 16 Total cellular RNA was isolated from cell preparations by using a single-step phenol/chloroform extraction procedure as reported elsewhere.20 Total cytoplasmic RNA (20 pg per sample) was size-fractionated on formaldehyde-denaturing 0.8% agarose gel and transferred to Nytran (Schleicher and Schuell). After W crosslinking, blots were hybridized to a 32P-labeled human IFNy cDNA probe prepared by random priming using a commercially available kit (Pharmacia, Piscataway, NJ). Conditions for hybridization and blot washing have been previously described? Quantitation of IFNy mRNA expression was calculated by using model 620 video densitometer (Bio-Rad, Richmond, CA).
Human IFNy analysis. After treatment of the cells with various agents for 24 or 48 hours, culture supernatants were harvested and human IFNy was assayed by radioimmunoassay (RIA; Centocor, Malvern, PA).
After treatment of cells with indicated agents, culture supernatants were harvested and supernatant IL-2 was assayed by enzyme-linked immunosorbent assay (ELISA Collaborative Research, Bedford, MA).
IgG, IgM, and IgA production were quantified using a standard ELISA procedure.
PMA was obtained from Sigma Chemical; (-)Indolactam-vZ1 and (+)Indolactam from LC Services Corporation (Woburn, MA); Ionomycin from Calbiochem (La Jolla, CA); and recombinant human IL-2 from Cetus Corp (Emeryville, CA).
RNA analysis.
RNA probes.
IL-2 analysis.
Zgproduction.
Reagents. indicate that PA682BM-1 cells express low levels of the p75 chain and higher levels of the p55 chain, JLP(c) cells express the p75 chain predominantly, and JD39 only express p55 (Table 1) . Stimulus requirement for IFNy production in human B-cell lines. To study the physiologic signal requirement for IFNy production, a wide panel of agents was tested for its ability to trigger IFNy secretion in the JLP(c) and PA682BM-1 ccll lines, including cytokines (IL-1, IL-2, IL-4, and IL-6), B-cell mitogens (lipopolysaccharide [LPS], antihuman IgM, and antihuman IgD antibodies), PKC activators [PMA and (-)Indolactam-v], and a calcium ionophore (ionomycin). As shown in Table 2 , maximum induction of IFNy in JLP(c) cells was detected after treatment with 1 pmol/L (-)Indolactam-v (178 U/mL) followed by 10 ng/mL PMA (111 U/mL) and 1, OOO U/mL of IL-2 (21 U/mL). These concentrations of the three agents were used in subsequent experiments because they were found to exert maximum induction of IFNy (Fig 2) . The effect of other cytokines and several B-cell mitogens listed in Table 2 was negligible. In addition, no synergistic effect between these agents at the concentrations tested and calcium ionophore was observed (data not shown). Similarly to Kinetics of IFNy secretion and IFNy mRNA qression. To determine the rate at which both IFNy protein and mRNA were synthesized, kinetic studies were first performed using PMA (10 ng/mL). Cells and supernatants were harvested at 2,4,8, 10, and 24 hours for JLP(c) cells and 8, 12, 24, 36, and 48 hours for PA682BM-1 cells after PMA addition. As shown in Figs 3 and 4 , the time course of IFNy cytoplasmic mRNA expression in these two cell lines For IFN-./ PRODUCTION IN HUMAN B- *Values for spontaneous expression were less than 1 U/mL based on the standard curve, but were consistently higher than the media control.
RESULTS
Documentation
tAt 48 hours, 6 U/mL of IFNy was detected. *At 48 hours, 39 U/mL of IFNy was detected.
was different. In JLP(c) cells, IFNy mRNA expression was detected in less then 2 hours and was maximal at 8 to 10 hours, whereas IFNy protein was detected at 8 hours. In PA682BM-1 cells, IFNy mRNA expression was about 20 times lower, was first detected at 8 hours, and peaked at 24 hours. IFNy protein secretion from this cell line was not detected until 48 hours after PMA addition (Table 3) . Similar kinetics of IFNy mRNA and protein were observed when (-)Indolactam-v was used as the inducing agent. In contrast to these results, a different time course of gene expression was observed when IL-2 was used as the inducing agent. In JLP(c) cells, IL-2 induced significant IFNy mRNA by 2 hours and maximal expression was at 4 hours. In contrast, PA682BM-1 cells express very little IFNy mRNA in response to IG2 and this RNA was only detected from 2 to 8 hours of IL-2 treatment. No IFNy protein was detected in PA682BM-1 culture supernatants after IL-2 treatment (Table 3) . Table 3 . IL-2R p75 mRNA was constitutively expressed in JLP(c) cells, was significantly enhanced by each of the three agents at 2 hours, and remained at the same high level until 10 hours of treatment. In contrast, p55 mRNA was expressed later at lower levels. Conversely, in PA682BM-1 cells, p55 mRNA was strongly induced by IL-2, PMA, or (-)Indolactam-v at 2 hours and remained at high levels until 36 to 48 hours postinduction. Furthermore, no constitutive p55 mRNA expression was observed in this line as analyzed by these standard Northern blot methods despite the detection of by densitometer analysis), but not by BB 10 or T4 (Fig SA) . The supernatants from the remaining cells in the same experiment were collected after 24 hours and assayed for human IFNy by RIA. The IFNy production was completely blocked by Tu27 (Fig SB) , whereas no difference was observed between samples from cultures that were treated with either T4 or BB 10. This result clearly established that interaction of IL-2 with the IL-2R chain is required for region if the SmBI site was completely nonmethylated. As shown in Fig 6 , distinct methylation differences were observed between the cell lines. The 8.6-kb band was completely cut by SnaBI in JLP(c) cells, indicating that this region is undermethylated in this cell line. This experiment also indicated that the 5' noncoding region was completely methylated in both the Jurkat and U937 cell lines, whjch is consistent with the observation that neither of these cell lines express IFNy (data not shown). Furthermore, in a Jurkat cell line that was able to produce IFNy, SmBI was able to cut the DNA (Fig 6B) , indicating that hypomethylation of this site has occurred in at least 50% of the genomic DNA. In addition, in the mouse T-cell line transfected with the human IFNy genomic DNA that constitutively produces human IFNy, SnaBI completely cut the IFNy DNA (Fig 6B) , indicating complete hypomethylation of the human DNA at this site. bromide (data not shown). However, the methylation pattern of PA682BM-1 DNA did not change after treatment with PMA or IL-2 for 48 hours (data not shown). Interestingly, partial hypomethylation was observed in all three B-cell lines. This result indicates that, while hypomethylation of the promoter can occur in B-cell lines and may correlate with constitutive gene expression, partial hypomethylation per se may not be sufficient for IFNy gene expression in B cells, at least as detected by the methods used in this study.
Effect of IL-2, P M , and (-)Indolactam
DISCUSSION
In the present study, we show that human B-cell lines can be triggered by (-)Indolactam-v, a PKC activator structur- The molecular events leading to IFNy expression by B-cell lines is presently unclear. We have previously shown that within the human IFNy genomic DNA at least two regions of DNA contain enhancer activity, one orientationindependent enhancer element in the 5' noncoding region, and another enhancer region in the first intron of the genomic DNA.3I The possibility that EBV transformation of B cells results in activation of one or both of these enhancer regions is currently under investigation. However, regardless of the molecular mechanism involved in IFNy gene expression, it is possible that IFNy expression in B cells may be more widespread than previously realized and may be correlated with inappropriate expression of specific EBV or when this inappropriate expression occurs in cells derived from patients with Burkitt's lymphoma and/or AIDS.
It has been previously shown that treatment of mouse and human T-cell lines with 5-azacytidine, an agent that prevents remethylation of DNA, results in reactivation of IFNy gene expres~ion.3~ Thus, the methylation state of the IFNy gene may also play a role in IFNy expression. Our results indicate that methylation differences are observed between JLP(c) and other cell lines that do not secrete detectable levels of IFNy spontaneously. Hypomethylation in the 5' noncoding region is detected in the JLP(c) B-cell line, suggesting that the methylation state of the promoter region may play an important role in the control of spontaneous IFNy gene expression in this cell line. In contrast, analysis of the methylation state of the human perforin gene did not show any differences in the methylation pattern between the cell lines, indicating that the JLP(c) cell line does not have an abnormal DNA methylation pattern (data not shown). However, it is clear from this study that complete hypomethylation of the genomic DNA is not required for inducible IFNy gene expression because the PA682BM-1 cell line and the Jurkat cell line that can produce IFNy exhibited only partial hypomethylation in this region. These data may reflect the methylation status of the different IFNy alleles within the specific cell line. Interestingly, the time course of expression of IFNy mRNA was shown to be quite different depending on the stimulus used. In JLP(c) cells, mRNA peaked at 2 to 4 hours after IL-2 treatment and at 8 to 10 hours after PMA treatment. The secretion of IFNy protein also followed a similar pattern. In comparison, PA682BM-1 cells can also be stimulated to secrete IFNy by PMA and (-)Indolactam-v with a time course similar to that observed in the JLP(c) cells. These data are consistent with our previous studies on human IFNy gene expression in a transfected mouse T-cell line that showed a greater IFNy mRNA stability after PMA treatment when compared with IL-2 treatment? Although the biochemical signal transduction For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From   IFN-y PRODUCTION IN HUMAN B-CELL LINES   731 pathways that have been activated upon treatment of the cells with the specific inducing agents have not been clarified at the molecular level, enhanced expression of IFNy after treatment with PMA and (-)Indolactam-v indicates that PKC is directly involved in this It was also observed that neither IgM nor IgD antibody affected IFNy production in these two B-cell lines, suggesting that the signal transduction pathways activated by these agents differ from those activated by IL-2, PMA, or indolactam.
The IFNy-secreting B-cell lines correspond to different early stages in the B-cell differentiation pathway, ie, pre-B cell (JLP(c)) and intermediate B cell (PA682BM-1) .23,41 In contrast with the intermediate B-cell line, the p r e -h e l l line exhibited a much higher capacity to be induced to secrete IFNy by IL-2, PMA, or (-)Indolactam-v. JD39, the control B-cell line, was further along the B-cell differentiation pathway and could not be induced to produce IFNy. Thus, the ability of human B cells to produce IFNy may be related to the differentiation state of the cell, and IFNy expression may be activated by certain viral infections or chromosomal translocations. The IFNy gene might only be expressed in early B cells, and IFNy gene expression may be gradually lost during the maturation process. This hypothesis awaits further investigation.
The observations of IFNy production in B-cell lines presented here raise the possibility that B-cell production of this immune effector molecule also may occur in vivo. It is conceivable that during certain viral infections, IFNy may be induced directly in B cells that are at an early stage of differentiation by IL-2 released by neighboring T cells. The released IFNy could possibly cause a more rapid maturation or protection of neighboring lymphocytes, thus slowing down the spread of virus or activating cytotoxic cells to destroy virally infected cells. These hypotheses will require further investigation of B-cell IFNy gene expression at the single-cell level.
